6.53
0.46 (7.58%)
| Penutupan Terdahulu | 6.07 |
| Buka | 6.08 |
| Jumlah Dagangan | 626,758 |
| Purata Dagangan (3B) | 257,893 |
| Modal Pasaran | 350,275,104 |
| Harga / Jualan (P/S) | 37.58 |
| Harga / Buku (P/B) | 0.740 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 12 Mar 2025 |
| Margin Operasi (TTM) | -4,293.31% |
| EPS Cair (TTM) | -5.58 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 36.20% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.39% |
| Nisbah Semasa (MRQ) | 44.63 |
| Aliran Tunai Operasi (OCF TTM) | -59.17 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -40.98 M |
| Pulangan Atas Aset (ROA TTM) | -16.23% |
| Pulangan Atas Ekuiti (ROE TTM) | -21.75% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Upstream Bio, Inc. | Bercampur | - |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -0.5 |
| Purata | 0.83 |
|
Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 19.80% |
| % Dimiliki oleh Institusi | 87.79% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Orbimed Advisors Llc | 31 Dec 2024 | 5,693,589 |
| Decheng Capital Llc | 31 Dec 2024 | 3,285,293 |
| Enavate Sciences Gp, Llc | 31 Dec 2024 | 2,459,703 |
| Bain Capital Life Sciences Investors, Llc | 31 Dec 2024 | 2,295,322 |
| Vr Adviser, Llc | 31 Dec 2024 | 2,295,319 |
| Samsara Biocapital, Llc | 31 Dec 2024 | 2,217,146 |
| Deep Track Capital, Lp | 31 Dec 2024 | 1,000,000 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 12 Mar 2025 | Pengumuman | Upstream Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights |
| 25 Feb 2025 | Pengumuman | Upstream Bio to Present at Upcoming March Investor Conferences |
| 11 Feb 2025 | Pengumuman | Automotive Security Leaders Must Take Immediate Action to Mitigate the Surging Cyber Threats--Upstream Report Reveals Critical Gaps |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |